vs
Side-by-side financial comparison of Gilead Sciences (GILD) and PG&E Corporation (PCG). Click either name above to swap in a different company.
Gilead Sciences is the larger business by last-quarter revenue ($7.9B vs $6.9B, roughly 1.2× PG&E Corporation). Gilead Sciences runs the higher net margin — 27.5% vs 12.9%, a 14.7% gap on every dollar of revenue. On growth, PG&E Corporation posted the faster year-over-year revenue change (15.0% vs 4.7%). Over the past eight quarters, Gilead Sciences's revenue compounded faster (8.9% CAGR vs 7.2%).
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
Pacific Gas and Electric Company (PG&E) is an American investor-owned utility (IOU). The company is headquartered at Kaiser Center, in Oakland, California. PG&E provides natural gas and electricity to 5.2 million households in the northern two-thirds of California, from Bakersfield and northern Santa Barbara County, almost to the Oregon and Nevada state lines.
GILD vs PCG — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $7.9B | $6.9B |
| Net Profit | $2.2B | $885.0M |
| Gross Margin | 79.5% | — |
| Operating Margin | 25.0% | 21.4% |
| Net Margin | 27.5% | 12.9% |
| Revenue YoY | 4.7% | 15.0% |
| Net Profit YoY | 22.4% | 39.6% |
| EPS (diluted) | $1.75 | $0.39 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $6.9B | ||
| Q4 25 | $7.9B | $6.8B | ||
| Q3 25 | $7.8B | $6.3B | ||
| Q2 25 | $7.1B | $5.9B | ||
| Q1 25 | $6.7B | $6.0B | ||
| Q4 24 | $7.6B | $6.6B | ||
| Q3 24 | $7.5B | $5.9B | ||
| Q2 24 | $7.0B | $6.0B |
| Q1 26 | — | $885.0M | ||
| Q4 25 | $2.2B | $670.0M | ||
| Q3 25 | $3.1B | $850.0M | ||
| Q2 25 | $2.0B | $549.0M | ||
| Q1 25 | $1.3B | $634.0M | ||
| Q4 24 | $1.8B | $674.0M | ||
| Q3 24 | $1.3B | $579.0M | ||
| Q2 24 | $1.6B | $524.0M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 79.8% | — | ||
| Q2 25 | 78.8% | — | ||
| Q1 25 | 76.9% | — | ||
| Q4 24 | 79.1% | — | ||
| Q3 24 | 79.1% | — | ||
| Q2 24 | 77.8% | — |
| Q1 26 | — | 21.4% | ||
| Q4 25 | 25.0% | 18.0% | ||
| Q3 25 | 42.8% | 19.3% | ||
| Q2 25 | 34.9% | 18.6% | ||
| Q1 25 | 33.6% | 20.4% | ||
| Q4 24 | 32.4% | 15.4% | ||
| Q3 24 | 11.8% | 17.3% | ||
| Q2 24 | 38.0% | 18.9% |
| Q1 26 | — | 12.9% | ||
| Q4 25 | 27.5% | 9.8% | ||
| Q3 25 | 39.3% | 13.6% | ||
| Q2 25 | 27.7% | 9.3% | ||
| Q1 25 | 19.7% | 10.6% | ||
| Q4 24 | 23.6% | 10.2% | ||
| Q3 24 | 16.6% | 9.7% | ||
| Q2 24 | 23.2% | 8.8% |
| Q1 26 | — | $0.39 | ||
| Q4 25 | $1.75 | $0.29 | ||
| Q3 25 | $2.43 | $0.37 | ||
| Q2 25 | $1.56 | $0.24 | ||
| Q1 25 | $1.04 | $0.28 | ||
| Q4 24 | $1.43 | $0.30 | ||
| Q3 24 | $1.00 | $0.27 | ||
| Q2 24 | $1.29 | $0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $68.0M | — |
| Total DebtLower is stronger | $24.9B | — |
| Stockholders' EquityBook value | $22.7B | — |
| Total Assets | $59.0B | — |
| Debt / EquityLower = less leverage | 1.10× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $68.0M | $713.0M | ||
| Q3 25 | $19.0M | $404.0M | ||
| Q2 25 | $69.0M | $494.0M | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | — | $940.0M | ||
| Q3 24 | — | $895.0M | ||
| Q2 24 | — | $1.3B |
| Q1 26 | — | — | ||
| Q4 25 | $24.9B | $57.4B | ||
| Q3 25 | $24.9B | — | ||
| Q2 25 | $24.9B | — | ||
| Q1 25 | $25.0B | — | ||
| Q4 24 | $26.7B | $53.6B | ||
| Q3 24 | $23.2B | — | ||
| Q2 24 | $23.3B | — |
| Q1 26 | — | — | ||
| Q4 25 | $22.7B | $32.5B | ||
| Q3 25 | $21.5B | $32.0B | ||
| Q2 25 | $19.7B | $31.2B | ||
| Q1 25 | $19.2B | $30.7B | ||
| Q4 24 | $19.3B | $30.1B | ||
| Q3 24 | $18.5B | $26.8B | ||
| Q2 24 | $18.3B | $26.3B |
| Q1 26 | — | — | ||
| Q4 25 | $59.0B | $141.6B | ||
| Q3 25 | $58.5B | $138.2B | ||
| Q2 25 | $55.7B | $136.4B | ||
| Q1 25 | $56.4B | $135.4B | ||
| Q4 24 | $59.0B | $133.7B | ||
| Q3 24 | $54.5B | $132.3B | ||
| Q2 24 | $53.6B | $130.8B |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 1.76× | ||
| Q3 25 | 1.16× | — | ||
| Q2 25 | 1.27× | — | ||
| Q1 25 | 1.30× | — | ||
| Q4 24 | 1.38× | 1.78× | ||
| Q3 24 | 1.26× | — | ||
| Q2 24 | 1.28× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.3B | — |
| Free Cash FlowOCF − Capex | $3.1B | — |
| FCF MarginFCF / Revenue | 39.4% | — |
| Capex IntensityCapex / Revenue | 2.6% | — |
| Cash ConversionOCF / Net Profit | 1.52× | — |
| TTM Free Cash FlowTrailing 4 quarters | $9.5B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.3B | $2.0B | ||
| Q3 25 | $4.1B | $2.9B | ||
| Q2 25 | $827.0M | $1.1B | ||
| Q1 25 | $1.8B | $2.8B | ||
| Q4 24 | $3.0B | $1.9B | ||
| Q3 24 | $4.3B | $3.1B | ||
| Q2 24 | $1.3B | $711.0M |
| Q1 26 | — | — | ||
| Q4 25 | $3.1B | $-1.2B | ||
| Q3 25 | $4.0B | $-80.0M | ||
| Q2 25 | $720.0M | $-2.0B | ||
| Q1 25 | $1.7B | $213.0M | ||
| Q4 24 | $2.8B | $-896.0M | ||
| Q3 24 | $4.2B | $526.0M | ||
| Q2 24 | $1.2B | $-1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 39.4% | -17.6% | ||
| Q3 25 | 51.0% | -1.3% | ||
| Q2 25 | 10.2% | -34.0% | ||
| Q1 25 | 24.8% | 3.6% | ||
| Q4 24 | 37.4% | -13.5% | ||
| Q3 24 | 55.2% | 8.9% | ||
| Q2 24 | 17.2% | -26.5% |
| Q1 26 | — | — | ||
| Q4 25 | 2.6% | 46.4% | ||
| Q3 25 | 1.9% | 46.9% | ||
| Q2 25 | 1.5% | 52.0% | ||
| Q1 25 | 1.6% | 44.0% | ||
| Q4 24 | 1.9% | 42.6% | ||
| Q3 24 | 1.9% | 43.8% | ||
| Q2 24 | 1.9% | 38.4% |
| Q1 26 | — | — | ||
| Q4 25 | 1.52× | 2.93× | ||
| Q3 25 | 1.35× | 3.35× | ||
| Q2 25 | 0.42× | 1.93× | ||
| Q1 25 | 1.34× | 4.49× | ||
| Q4 24 | 1.67× | 2.87× | ||
| Q3 24 | 3.44× | 5.41× | ||
| Q2 24 | 0.82× | 1.36× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GILD
| Other | $3.4B | 43% |
| HIV Products Biktarvy | $3.3B | 41% |
| HIV Products Odefsey | $239.0M | 3% |
| Liver Disease Products Other Liver Disease | $170.0M | 2% |
| HIV Products Other HIV | $155.0M | 2% |
| Other Products Yescarta | $150.0M | 2% |
| Liver Disease Products Vemlidy | $149.0M | 2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 2% |
| HIV Products Symtuza Revenue Share | $98.0M | 1% |
| Veklury | $80.0M | 1% |
| Cell Therapy Products Tecartus | $32.0M | 0% |
| Royalty Contract And Other | $22.0M | 0% |
PCG
| Electric | $5.0B | 72% |
| Other | $1.9B | 28% |
